알라딘릴게임 사이트 6.rmq138.top 바로가기 오션파라다이스 게임, 황금성제주도

오션파라다이스7바다이야기게임다운로드손오공 릴게임황금성 사이트

오공슬롯 80.rmq138.top 온라인배경

슬롯사이트 2.rmq138.top 사이트추천

황금성배당줄 42.rmq138.top 스핀모바게임랜드

야마토게임 74.rmq138.top 릴게임손오공

양귀비게임설명 83.rmq138.top 다빈치

릴게임설치 23.rmq138.top 카카오릴게임

릴게임야마토 39.rmq138.top 먹튀피해복구

신천지게임 44.rmq138.top 오징어 릴게임

슬롯버그 98.rmq138.top 릴게임횡금성

프라그마틱무료메타2 98.rmq138.top 다빈치 릴게임 먹튀

바로가기 go !! 바로가기 go !!

하이클래스릴게임 황금성나비 야마토게임사이트 바다이야기 확률 릴게임바다이야기 바다이야기 디시 우주전함야마토2199 무료 바다이야기 스톰게임 모바일신천지모바일 우주전함야마토2199 오리지널황금성 오리지날 야마토 오션슬롯주소 릴게임알라딘 777 무료 슬롯 머신 황금성게임예시 바다이야기기계가격 오리 지날 바다 온라인 슬롯 하는 법 프라그마틱 무료체험 릴게임 신천지사이트 올벳매거진 모바일야마토 바다이야기 먹튀 돈 받기 모바일파칭코 슬롯사이트순위 바다이야기 온라인 바다이야기 무료머니 릴게임무료 파칭코 어플 한게임포커 릴게임가입머니 신천지무료 야마토 2 다운로드 오락실게임 실시간바둑이 골드몽 손오공예시 릴게임무료 바다이야기게임기 황금성게임랜드 황금성 무료머니 백경게임하는곳주소 바다이야기 다운로드 릴게임동영상 일본빠찡꼬 신바다이야기 야마토게임사이트 바다이야기게임하기 해저이야기사이트 파칭코 어플 릴게임 먹튀보증 다빈치다운로드 야마토게임동영상 해외축구일정 온라인황금성 정글북 바다이야기 apk 한게임머니파는곳 야마토릴 슬롯릴게임 체리마스터게임 체리게임바둑이 온라인오션파라다이스 카카오야마토먹튀 다빈치릴게임먹튀 슬롯 머신 이기는 방법 인터넷오션파라다이스 하이로우하는법 슬롯머신 777 백경다운로드 카지노 슬롯머신 전략 오션파라다이스하는방법 황금성 게임랜드 PC 슬롯 머신 게임 무료 야마토 게임 일본빠칭코게임 상품권릴게임 카지노 슬롯머신 무료충전 바다이야기 황금성예시 모바일야마토 오션파라다이스3 오션파라 다이스예시 게임몰 릴게임 안전검증릴게임 야마토창공 무료충전 릴 게임 야마토다운 바다신2 게임 릴114 온라인 릴게임 손오공 야마토게임 하기 인터넷오션파라다이스 인터넷오션게임 바다이야기사이트 바다이야기 게임 방법 바다이야기 파칭코 안전 검증 릴게임 야마토노하우 오션파라다이스릴게임 손오공바다이야기 황금성9 오션파라다이스게임 알라딘 무료백경 황금포카성 백경사이트 사설배팅 알라딘사이트 릴게임횡금성 유희왕 황금성 체리마스터 비법 프라그마틱 무료체험 져스트릴게임 온라인야마토게임 슬롯버프 바다이야기 게임 방법 온라인오션파라다이스 사설배팅 빠칭코게임다운로드 바다이야기조작 바다시즌7 체리게임 This article was released as Pharm Edaily Premium Content on October 15, 2025, at 7:10 AM.


[Kim Saemi, Edaily Reporter] On October 14, the bio-healthcare sector saw shares of MYUNGIN PHARM CO., LTD. rebound, while RP Bio Inc. rose sharply on expectations of a corporate value re-rating. In contrast, VIVOZON PHARMACEUTICAL, CO., LTD. plunged after announcing a 50 bil 실매물닷컴 lion won rights offering for existing shareholders.
MYUNGIN PHARM rebounds after four sessions amid valuation debate
According to KG Zeroin’s MP Doctor (formerly Market Point), MYU 보금자리론 금리 NGIN PHARM closed at 109,700 won, up 11,700 won (11.94%) from the previous day.
The company, well known for its gum disease supplement Igatan, had recorded a “double” (stock price doubling f 은행 금리 담합 rom IPO price) on its first trading day on the KOSPI on October 1, but then declined for three consecutive sessions. With today’s rally, MYUNGIN PHARM’s market capitalization reached 1.61 trillion won 메리츠증권 ―below the 1.78 trillion won peak on listing day, but back to levels seen on October 2.



Stock trend of MYUNGIN PHARM CO., LTD. after IPO (Source: KG Zero 변동금리 적용 in MP Doctor)



MYUNGIN PHARM’s debut market cap of nearly 1.8 trillion won drew strong attention from the biopharma sector. On that day, it ranked sixth among KOSPI-listed pharmaceutical companies, following Samsung Biologics, Celltrion, Yuhan Corporation, SK bioscience, and Hanmi Pharm. Co., Ltd.

Some market watchers have raised concerns over possible overvaluation, noting that the company’s 2023 revenue was 269.4 billion won, while Chong Kun Dang―which reported sales exceeding 1.58 trillion won that year―had a market cap of just 1.13 trillion won.
The company stated that there was “no specific reason identified” for the day’s stock surge. A MYUNGIN PHARM spokesperson said, “We are not aware of any particular factor driving today’s increase.”
Separately, the firm disclosed that CEO Haeng-Myung Lee, its largest shareholder, holds 10.776 million shares, representing a 73.81% stake.
RP Bio Inc. jumps 13% on strong earnings outlook
RP Bio Inc. closed at 8,010 won, up 940 won (13.3%)―the largest percentage gain among KOSDAQ―listed pharmaceutical and biotech firms that day.
The rally was likely fueled by an analyst report highlighting strong earnings growth and a potential re-rating of the company’s valuation.



KOSDAQ top gainers by share price increase on October 14 (Source: KG Zeroin MP Doctor)



According to researcher Yoon-Seok Chae at the Korea Investor Relations Service, RP Bio recorded an earnings per share (EPS) growth of 603.8%, signaling a clear turnaround in performance. He pointed to new soft capsule formulations and expansion into individually approved functional materials as key drivers of future growth.

Chae noted that since RP Bio’s KOSDAQ listing in September 2022, its price-to-book ratio (PBR) had fluctuated between 0.4x and 1.5x. Based on projected 2025 earnings, its current PBR of 0.6x positions the stock near the lower end of that range.
The company is expected to post 133.8 billion won in revenue this year, up 7.9% year-over-year, and turn an operating profit of 6.1 billion won. The health functional food segment is projected to grow 17.5% year-over-year, accounting for over 63% of total sales.
An RP Bio official commented, “Current valuation indicators such as PBR and PSR do not fully reflect our explosive EPS growth,” adding that the company “plans to accelerate corporate value re-rating by commercializing new formulations and individually approved ingredients.”
VIVOZON PHARMACEUTICAL tumbles 21% on 50 billion won rights offering
In contrast, VIVOZON PHARMACEUTICAL, CO., LTD. tumbled 21.3% to close at 5,100 won, following its announcement of a capital increase.



Recent stock trend of VIVOZON PHARMACEUTICAL, CO., LTD. (Source: KG Zeroin MP Doctor)



On October 13, the company disclosed plans for a 50 billion won rights offering through a combination of shareholder allocation and public subscription. The new share issuance totals 10.615 million shares―equivalent to 21.2% of its outstanding 50.1 million shares. Each existing share will be allocated 0.21423 new shares. The underwriter, NH Investment & Securities, will acquire any unsubscribed shares.

VIVOZON’s lead pipeline is Unafra Inj., a non-opioid analgesic that has yet to be commercialized. As a result, the company continues to post net losses and fell into capital impairment earlier this year. However, VIVOZON expects sales contributions from Unafra Inj.―designated as Korea’s 38th innovative new drug―to begin in the second half, improving results.
From next year, the company aims to achieve profitability through full-scale Unafra Inj. commercialization.
VIVOZON stated that the capital increase aims to strengthen business sustainability and improve financial capacity. Of the 50 billion won raised, 23 billion will be used for debt repayment and 25.8 billion for working capital.
Within working capital, 7 billion won will be spent on acquiring exclusive injectable rights for Unafra Inj. from VIVOZON Co., Ltd., the parent company. The total contract value is 11 billion won, excluding royalties, with 2 billion already paid upfront. Additional payments of 1 billion each were made upon Phase 3 approval and marketing authorization submission.
A company official added, “There are no other issues affecting the stock decline apart from the rights offering.”
김새미 (bird@edaily.co.kr)